Two-Pronged attack on advanced cancers shows promise

This study is testing whether combining two different cancer drugs (BL-B01D1 and a PD-1 antibody) works better than current treatments for people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. Researchers will enroll 570 patients to see if this combination can shrink tumors and control cancer growth while monitoring side effects. The goal is to find a more effective treatment option for cancers that are difficult to treat.